MARKETS
Analyst Actions

Lake Street Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $10

Sep 15, 2026 · 11:56 AM ET· updated 1d ago

Lake Street analyst Thomas Flaten initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $10.

Share
Why It Matters

A research company called Lake Street started following Alterity Therapeutics and thinks it looks good. This can hint that the company might have something promising, but the stock could move either way.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.